Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies

Clinical and Experimental Immunology, Supplement

Volumn 104, Issue SUPPL. 1, 1996, Pages 55-60

  Dalakas, M C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myopathies; Intravenous immune globulin; Polymyositis

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN;

CLINICAL TRIAL; CONFERENCE PAPER; DERMATOMYOSITIS; HUMAN; IMMUNOCYTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; MUSCLE BIOPSY; MYOPATHY; PHAGOCYTOSIS; POLYMYOSITIS; PRIORITY JOURNAL;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYOSITIS;

EID: 0029985878     PISSN: 09642536     EISSN: None     Source Type: Journal    
DOI: 10.1111/cei.1996.104.s1.55     Document Type: Article

References (35)

1. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991; 325:1487-98.
2. Dalakas MC. Inflammatory myopathies: pathogenesis and treatment. Neuropharmacology 1992; 5:327-51.
3. Engel AG, Kohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndrome. In: Engel AG, Franzini-Armstrong C, eds. Myology. New York:McGraw-Hill, 1994: 1335-83.
4. Hohlfeld R, Goebels N, Engel AG. Cellular mechanisms in inflammatory myopathies. In: Mastaglia FL ed. Baillière's Clinical Neurology. London:W.B. Saunders Co., 1993: 617-36.
5. Karpati G, Carpenter S. Pathology of the inflammatory myopathies. In: Mastaglia FL, ed. Baillière's Clinical Neurology. London:W.B. Saunders Co., 1993: 527-56.
6. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995; 37(Suppl):74-86.
7. Engel AG, Emslie-Smith AM. Inflammatory myopathies. Curr Opin Neurol Neurosurg 1989; 2:695-700.
8. Lotz BP, Engel AG, Nishino H et al. Inclusion body myositis. Brain 1989; 112:727-42.
9. Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol 1993; 13:256-63.
10. Dalakas MC. Treatment of polymyositis and dermatomyositis with corticosteroids: a first therapeutic approach. In: Dalakas MC, ed. Polymyositis and Dermatomyositis. Boston:Butterworths, 1988: 235-53.
11. Dalakas MC. Treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 1989; 1:443-9.
12. Dalakas MC. How to diagnose and treat the inflammatory myopathies. Semin Neurol 1994; 14:137-45.
13. Dalakas MC. Current treatment of the inflammatory myopathies. Curr Opin Rheumatol 1994; 6:595-601.
14. Grau JM, Herrero C, Casademont J et al. Cyclosporine A as first choice for dermatomyositis. J Rheumatol 1994; 21:381-2.
15. Miller FW, Leitman SF, Cronin ME et al. A randomized double-blind controlled trial of plasma exchange and leukapheresis in patients with polymyositis/dermatomyositis. N Engl J Med 1992; 326:1380-4.
16. Cronin ME, Miller FW, Hicks JE et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16:1225-8.
17. Bombardieri S, Hughes GRV, Neri R et al. Cyclophosphamide in severe polymyositis. Lancet 1989; 335:1138-9.
18. Roifman CM, Schaffer FM, Wachsmuth SE et al. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. J Am Med Assoc 1987; 258:513-5.
19. Cherin P, Herson S. Wechsler B et al. Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients. Am J Med 1991; 91:162-8.
20. Lang B, Laxer RM, Murphy G et al. Treatment of dermatomyositis with intravenous immunoglobulin. Am J Med 1991; 91:169-72.
21. Jan S, Beretta S, Moggio M et al. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 1992; 55:60-4.
22. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: A quantitative study. Ann Neurol 1990; 27:343-56.
23. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94:1729-35.
24. Stein DP, Dalakas MC. Intercellular adhesion molecule-1 expression is upregulated in patients with dermatomyositis (DM). Ann Neurol 1993; 34:268 (Abstract).
25. Debleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neurop Exp Neurol 1994; 53:369-76.
26. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000.
27. Dalakas MC. Intravenous immune globulin for dermatomyositis. N Engl J Med 1994; 330:1392-3.
28. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:5-19.
29. Leon-Monzon M, Dalakas MC. Interleukin-1 (IL-1) is toxic to human muscle. Neurology 1994; 44 (Suppl):132.
30. Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991; 29:498-507.
31. Drosos AA, Dalakas MC. Expression of activation markers on endomysial macrophages in patients with inflammatory myopathies. Arthritis Rheum 1993; 36:5256.
32. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986; 17:704-21.
33. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class-1 antigen expression, immunolocalization of interferon subtypes and T-cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20:224-31.
34. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43:876-9.
35. Dalakas MC, Dambrosia JM, Sekul EA et al. The efficacy of IVIG in patients with inclusion body myositis. Neurology 1995; 45 (Suppl):208 (Abstract).